Cardiopulmonary indications for endothelin receptor antagonists: review of recent efficacy trials.

No abstract is available for this paper.

• Publication year

  1997

• Venue

  Expert Opinion on Investigational Drugs

• Publication date

  1997-05-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1517/13543784.6.5.475PMID 15989614
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Nonpeptide endothelin receptor antagonists. VIII: attentuation of acute hypoxia-induced pulmonary hypertension in the dog.

  1997cited by this paper
• Concomitant endothelin receptor subtype-A blockade during the progression of pacing-induced congestive heart failure in rabbits. Beneficial effects on left ventricular and myocyte function.

  1997cited by this paper
• Pulmonary hypertension caused by congestive heart failure is ameliorated by long-term application of an endothelin receptor antagonist. Increased expression of endothelin-1 messenger ribonucleic acid and endothelin-1-like immunoreactivity in the lung in congestive heart failure in rats.

  1996cited by this paper
• The endothelin system and its potential as a therapeutic target in cardiovascular disease.

  1996cited by this paper
• Molecular pharmacology of endothelin converting enzymes.

  1996cited by this paper
• Endothelin Receptor Antagonist Increases Cerebral Perfusion and Reduces Ischaemic Damage in Feline Focal Cerebral Ischaemia

  1996cited by this paper
• Vasodilator effects of endothelin-converting enzyme inhibition and endothelin ETA receptor blockade in chronic heart failure patients treated with ACE inhibitors.

  1996cited by this paper
• The endothelins in the pulmonary system.

  1996cited by this paper
• Discovery and optimization of a novel class of orally active nonpeptidic endothelin-A receptor antagonists.

  1996cited by this paper
• Telemetry monitoring of pulmonary arterial pressure in freely moving rats.

  1996cited by this paper
• California dreamin' 'bout endothelin: emerging new therapeutics.

  1996cited by this paper
• Inhibition of myocardial endothelin pathway improves long-term survival in heart failure

  1996cited by this paper
• Pharmacological characterization of A-127722: an orally active and highly potent ETA-selective receptor antagonist.

  1996cited by this paper
• Short-term hemodynamic effects of endothelin receptor blockade in dogs with chronic heart failure.

  1996cited by this paper
• Role of nitric oxide and endothelin-1 in monocrotaline-induced pulmonary hypertension in rats.

  1995cited by this paper
• The role of endothelin in experimental cerebral vasospasm.

  1995cited by this paper
• Pharmacology of a non‐selective ETA and ETB receptor antagonist, TAK‐044 and the inhibition of myocardial infarct size in rats

  1995cited by this paper
• Endothelin induced collagen remodeling in experimental pulmonary hypertension.

  1995cited by this paper
• Endothelin-converting Enzyme-2 Is a Membrane-bound, Phosphoramidon-sensitive Metalloprotease with Acidic pH Optimum (*)

  1995cited by this paper
• Elevated levels of plasma endothelin-1 in young patients with pulmonary hypertension caused by congenital heart disease are decreased after successful surgical repair.

  1995cited by this paper
• Endothelin receptor antagonists in a beagle model of pulmonary hypertension: contribution to possible potential therapy?

  1995cited by this paper
• Structure-activity relationships of cyclic pentapeptide endothelin A receptor antagonists.

  1995cited by this paper
• Effects of the ETA/ETB receptor antagonist, bosentan on endothelin‐1‐induced myocardial ischaemia and oedema in the rat

  1995cited by this paper
• Evidence for endothelin-1-mediated vasoconstriction in severe chronic heart failure.

  1995cited by this paper
• Endothelin ETA and ETB receptors cause vasoconstriction of human resistance and capacitance vessels in vivo.

  1995cited by this paper
• Blockade of endothelin-converting enzyme reduces pulmonary hypertension after cardiopulmonary bypass and circulatory arrest.

  1995cited by this paper
• Discovery of a novel series of orally active non-peptide endothelin-A (ETA) receptor-selective antagonists.

  1995cited by this paper
• Role of endothelin-1 in beagles with dehydromonocrotaline-induced pulmonary hypertension.

  1995cited by this paper
• Endothelin ETA and ETB mRNA and receptors expressed by smooth muscle in the human vasculature: majority of the ETA sub‐type

  1995cited by this paper
• Characterization of three non‐peptide endothelin receptor ligands using human cloned ETA and ETB receptors

  1994cited by this paper
• SB 209670, a rationally designed potent nonpeptide endothelin receptor antagonist.

  1994cited by this paper
• Human saphenous vein contains both endothelin ETA and ETB contractile receptors.

  1994cited by this paper
• ECE-1: a membrane-bound metalloprotease that catalyzes the proteolytic activation of big endothelin-1.

  1994cited by this paper
• International Union of Pharmacology nomenclature of endothelin receptors.

  1994cited by this paper
• Subtypes of endothelin ETA and ETB receptors mediating venous smooth muscle contraction.

  1994cited by this paper
• Characterization of endothelin (ET) receptors in the isolated gall bladder of the guinea‐pig: evidence for an additional ET receptor subtype

  1994cited by this paper
• Relation between endothelin-1 spillover in the lungs and pulmonary vascular resistance in patients with chronic heart failure.

  1994cited by this paper
• Two distinct human endothelin B receptors generated by alternative splicing from a single gene.

  1994cited by this paper
• Biochemical and pharmacological profile of a potent and selective endothelin B-receptor antagonist, BQ-788.

  1994cited by this paper
• Cloning and functional expression of endothelin-converting enzyme from rat endothelial cells.

  1994cited by this paper
• Effects of a new endothelin antagonist, TAK-044, on post-ischemic acute renal failure in rats.

  1994cited by this paper
• Pharmacological characterization of bosentan, a new potent orally active nonpeptide endothelin receptor antagonist.

  1994cited by this paper
• Use of the endothelin antagonists BQ‐123 and PD 142893 to reveal three endothelin receptors mediating smooth muscle contraction and the release of EDRF

  1993cited by this paper
• ETA and ETB receptors coexist on rabbit pulmonary artery vascular smooth muscle mediating contraction.

  1993cited by this paper
• BQ-123, a peptidic endothelin ETA receptor antagonist, prevents the early cerebral vasospasm following subarachnoid hemorrhage after intracisternal but not intravenous injection.

  1993cited by this paper
• Growth regulatory properties of endothelins.

  1993cited by this paper
• Expression of endothelin-1 in the lungs of patients with pulmonary hypertension.

  1993cited by this paper
• Contribution of endogenous endothelin-1 to the progression of cardiopulmonary alterations in rats with monocrotaline-induced pulmonary hypertension.

  1993cited by this paper
• Endothelin-1 stimulates DNA synthesis and proliferation of pulmonary artery smooth muscle cells.

  1992cited by this paper
• Molecular characterization of endothelin receptors.

  1992cited by this paper
• Protective effect of a selective endothelin receptor antagonist, BQ-123, in ischemic acute renal failure in rats.

  1992cited by this paper
• Endothelin 1: Mitogenic Activity on Pulmonary Artery Smooth Muscle Cells and Release from Hypoxic Endothelial Cells

  1992cited by this paper
• Concentration- and time-dependence of phosphoinositide hydrolysis induced by endothelin-1 in relation to the positive inotropic effect in the rabbit ventricular myocardium.

  1992cited by this paper
• The molecular mechanisms of cardiovascular and renal regulation by endothelin peptides.

  1992cited by this paper
• Plasma Endothelin Correlates With the Extent of Pulmonary Hypertension in Patients With Chronic Congestive Heart Failure

  1992cited by this paper
• Organization, structure, chromosomal assignment, and expression of the gene encoding the human endothelin-A receptor.

  1992cited by this paper
• Protective effect of a selective endothelin receptor antagonist, BQ-123, in ischemic acute renal failure in rats.

  1992cited by this paper
• Molecular characterization of endothelin receptors.

  1992cited by this paper
• Endothelin and increased contractility in adult rat ventricular myocytes. Role of intracellular alkalosis induced by activation of the protein kinase C-dependent Na(+)-H+ exchanger.

  1991cited by this paper
• Endothelium‐dependent mesenteric vasorelaxant effects and systemic actions of endothelin (16–21) and other endothelin‐related peptides in the rat

  1991cited by this paper
• Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure.

  1991cited by this paper
• Hemodynamic and pharmacological evaluation of the vasodilator and vasoconstrictor effects of endothelin-1 in rats.

  1990cited by this paper
• Cloning and expression of a cDNA encoding an endothelin receptor

  1990cited by this paper
• Cloning of a cDNA encoding a non-isopeptide-selective subtype of the endothelin receptor

  1990cited by this paper
• A novel potent vasoconstrictor peptide produced by vascular endothelial cells

  1988cited by this paper
• Endothelin stimulates phospholipase C in cultured vascular smooth muscle cells.

  1988cited by this paper
• Endothelin stimulates c‐fos and c‐myc expression and proliferation of vascular smooth muscle cells

  1988cited by this paper
• Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS).

  1987cited by this paper
• Effect of Vasodilator Therapy on Mortality in Chronic Congestive Heart Failure

  1986cited by this paper
• Effect of vasodilator therapy on mortality in chronic congestive heart failure. Results of a Veterans Administration Cooperative Study.

  1986cited by this paper
• Pulmonary hypertension in children: perioperative management

  1986cited by this paper
• Changes in pulmonary structure and function induced by monocrotaline intoxication.

  1981cited by this paper

• Studies on Coronary Arteriopathy in Dogs Following Administration of CI-1020, an Endothelin A Receptor Antagonist

  2001cites this paper
• Attenuation of pulmonary vascular hypertension and cardiac hypertrophy with sitaxsentan sodium, an orally active ET(A) receptor antagonist.

  2000cites this paper
• Endothelin-A-receptors in human aorta and pulmonary arteries are downregulated in patients with cardiovascular disease: an adaptive response to increased levels of endothelin-1?

  2000influential citation
• SMI meeting: innovations in cardiovascular drugs. March 3-4, 1999, London, UK.

  1999cites this paper
• Coronary Arteriopathy in Monkeys Following Administration of CI-1020, an Endothelin A Receptor Antagonist

  1999cites this paper
• Efficacy of CI-1020, an endothelin-A receptor antagonist, in hypoxic pulmonary hypertension.

  1998cites this paper
• Endothelin and Calcium Signaling

  1998cites this paper
• Chapter 7. Endothelin Inhibitors

  1997cites this paper